These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 215528)

  • 1. Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value.
    Desgranges C; de-The G
    IARC Sci Publ (1971); 1978; (20):459-69. PubMed ID: 215528
    [No Abstract]   [Full Text] [Related]  

  • 2. IgA and nasopharyngeal carcinoma.
    Desgranges C; De-The G
    IARC Sci Publ (1971); 1978; (24 Pt 2):883-91. PubMed ID: 221410
    [No Abstract]   [Full Text] [Related]  

  • 3. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
    Henle W; Henle G; Ho JH
    IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
    [No Abstract]   [Full Text] [Related]  

  • 4. IgA antibodies to Epstein-Barr viral capsid antigens in saliva of nasopharyngeal carcinoma patients.
    Ho HC; Ng MH; Kwan HC
    Br J Cancer; 1977 Jun; 35(6):888-90. PubMed ID: 194619
    [No Abstract]   [Full Text] [Related]  

  • 5. Malaria antibody levels in patients with nasopharyngeal carcinoma.
    Yadav M; Prasad U
    Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV specific secretory IgA in saliva of NPC patients. Presence of secretory piece in epithelial malignant cells.
    Desgranges C; Li JY; De-Thé
    Int J Cancer; 1977 Dec; 20(6):881-6. PubMed ID: 201574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein--Barr virus-associated antibodies in IgG and IgA of nasopharyngeal carcinoma patients.
    Yang CS; Yang HM; Yeh YS; Lynn TC
    Comp Immunol Microbiol Infect Dis; 1979; 2(2-3):167-75. PubMed ID: 228890
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The capsid antigen of Epstein-Barr virus in nasopharyngeal carcinomas: comparison of serum antibody titre, cellular antigen content and histopathology.
    Falser N
    Arch Otorhinolaryngol; 1984; 239(1):15-23. PubMed ID: 6318710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetic and antigenic basis for the IgA antibody response to Epstein-Barr viral capsid antigen.
    Ng MH; Ho HC; Kwan HC
    IARC Sci Publ (1971); 1978; (20):449-58. PubMed ID: 215527
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
    Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
    J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals.
    Zhu XX; Zeng Y; Wolf H
    Int J Cancer; 1986 May; 37(5):689-91. PubMed ID: 3009331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus specific antibodies in patients with IgA nephropathy.
    Wu AY; Lau YK; Chia KB; Lim CH
    Singapore Med J; 1988 Jun; 29(3):257-60. PubMed ID: 2847323
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical evaluation of EBV serology in American patients with nasopharyngeal carcinoma.
    Pearson GR; Coates HL; Neel HB; Levine P; Ablashi D; Easton J
    IARC Sci Publ (1971); 1978; (20):439-48. PubMed ID: 215526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
    Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW
    Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [125I] Clq-binding activity and its relationship with anti-Epstein--Barr virus antibodies in sera from nasopharyngeal carcinoma patients.
    Lamelin JP; Vincent C; Souissi T; Revillard JP
    Eur J Cancer (1965); 1979 Feb; 15(2):163-71. PubMed ID: 220051
    [No Abstract]   [Full Text] [Related]  

  • 17. The significance of serologic test for EB-virus antibody in occult type nasopharyngeal carcinoma.
    Furukawa M; Takimoto T; Morishita K; Komori T; Ishiguro H; Umeda R
    Auris Nasus Larynx; 1983; 10(1):43-8. PubMed ID: 6311149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical usefulness of the serological study of IgG antibodies and IgA against the antigens associated with the Epstein-Barr virus in patients with nasopharyngeal carcinoma].
    Amador García JM; Mendoza Montero J; Expósito Hernández J; Salinero Hernández J; Esquivias López-Cuerpo J; Ballesteros García P
    Acta Otorrinolaringol Esp; 1992; 43(1):31-6. PubMed ID: 1316136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of antibodies to Epstein-Barr virus DNase and viral capsid antigen for prognostication of patients with nasopharyngeal carcinoma.
    Hsu MM; Chen JY; Chen CJ
    Taiwan Yi Xue Hui Za Zhi; 1988 Oct; 87(10):984-8. PubMed ID: 2853721
    [No Abstract]   [Full Text] [Related]  

  • 20. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma.
    Cheng YC; Chen JY; Glaser R; Henle W
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6162-5. PubMed ID: 6255477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.